ImmunityBio IBRX
NASDAQ IBRX
$8.07 -0.11 (-1.40%)
As of: Sep 4, 2026 · 3:59 PM EDT

ImmunityBio (IBRX) Operating Income Growth (3y) (2017 - 2026)

Analysis

ImmunityBio (IBRX) Operating Income Growth (3y) (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 8.36%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 89.72%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 24.14%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 44.54%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 44.34%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -18.82%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 81.27%
10 ImmunityBio 8.51 Bn 8.15 Bn 50.94 Mn 10.18%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10.18%
Mar 31, 2026 14.48%
Dec 31, 2025 8.67%
Sep 30, 2025 15.07%
Jun 30, 2025 3.62%
Mar 31, 2025 12.44%
Dec 31, 2024 4.34%
Sep 30, 2024 -0.60%
Jun 30, 2024 -4.96%
Mar 31, 2024 -3.34%
Dec 31, 2023 -40.35%
Sep 30, 2023 -6.75%
Jun 30, 2023 -18.70%
Mar 31, 2023 -44.87%
Dec 31, 2022 -74.02%
Sep 30, 2022 -78.13%
Jun 30, 2022 -66.35%
Mar 31, 2022 -73.63%
Dec 31, 2021 -64.78%
Sep 30, 2021 -48.43%